

James L M Ferrara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1722730/publications.pdf>

Version: 2024-02-01

60
papers

7,385
citations

147801

31
h-index

161849

54
g-index

60
all docs

60
docs citations

60
times ranked

7163
citing authors

#	ARTICLE	IF	CITATIONS
1	Tisch Cancer Institute Scholars Program: Mentored Cancer Research Training Pipeline for Medical Students. <i>Journal of Cancer Education</i> , 2022, 37, 1166-1171.	1.3	4
2	Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. <i>Blood Advances</i> , 2022, 6, 3707-3715.	5.2	9
3	Mannan-Binding Lectin Promotes Murine Graft-versus-Host Disease by Amplifying Lipopolysaccharide-Initiated Inflammation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 472.e1-472.e11.	1.2	0
4	Graft-versus-host disease: establishing IL-33 as an important costimulatory molecule. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	2
5	Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. <i>Journal of Clinical Oncology</i> , 2021, 39, 1865-1877.	1.6	111
6	Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 988.e1-988.e7.	1.2	10
7	Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers. <i>Bone Marrow Transplantation</i> , 2021, 56, 2869-2870.	2.4	3
8	New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD). <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 761-771.	3.4	10
9	Obesity induces gut microbiota alterations and augments acute graft-versus-host disease after allogeneic stem cell transplantation. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	29
10	Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant. <i>Leukemia</i> , 2020, 34, 1898-1906.	7.2	16
11	Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. <i>Blood</i> , 2020, 135, 97-107.	1.4	56
12	Biomarker-guided preemption of steroid-refractory graft-versus-host disease with Î±1-antitrypsin. <i>Blood Advances</i> , 2020, 4, 6098-6105.	5.2	24
13	MAGIC biomarkers of acute graft-versus-host disease: Biology and clinical application. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 101111.	1.7	13
14	Acute Graft-Versus-Host Disease (aGVHD, Non-Relapse Mortality) Risk Prediction Assay: Validation and Initial Reference Lab Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S226.	2.0	1
15	The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease. <i>Blood Advances</i> , 2019, 3, 4034-4042.	5.2	63
16	Biomarkers in acute graft-versus-host disease: new insights. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071989135.	2.5	25
17	The MAGIC Algorithm Probability (MAP): A Novel Laboratory Biomarker for the Response to Treatment of Acute Graft-Versus-Host Disease. <i>Blood</i> , 2019, 134, 367-367.	1.4	0
18	Obesity-Induced Microbiome Alterations Result in Severe Gastrointestinal Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2019, 134, 1922-1922.	1.4	0

#	ARTICLE	IF	CITATIONS
19	MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD. <i>Blood</i> , 2018, 131, 2846-2855.	1.4	140
20	Microbial metabolite sensor GPR43 controls severity of experimental GVHD. <i>Nature Communications</i> , 2018, 9, 3674.	12.8	102
21	Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. <i>Blood Advances</i> , 2018, 2, 1882-1888.	5.2	27
22	GVHD: biology matters. <i>Blood Advances</i> , 2018, 2, 3411-3417.	5.2	38
23	Acute graft-versus-host disease of the gut: considerations for the gastroenterologist. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 711-726.	17.8	110
24	T Cell-Mediated Rejection of Human CD34+ Cells Is Prevented by Costimulatory Blockade in a Xenograft Model. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2048-2056.	2.0	4
25	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. <i>Blood</i> , 2016, 128, 2350-2358.	1.4	43
26	Therapeutic targets and emerging treatment options in gastrointestinal acute graft-versus-host disease. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 469-484.	0.8	4
27	International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 4-10.	2.0	487
28	Biomarkers Predict Graft-Vs-Host Disease Outcomes Better Than Clinical Response after One Week of Treatment. <i>Blood</i> , 2016, 128, 510-510.	1.4	0
29	All pain, no gain: Tc17 phantoms in GVHD. <i>Blood</i> , 2015, 126, 1525-1526.	1.4	5
30	Programmed Death-1 Controls T Cell Survival by Regulating Oxidative Metabolism. <i>Journal of Immunology</i> , 2015, 194, 5789-5800.	0.8	104
31	A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. <i>Lancet Haematology</i> , 2015, 2, e21-e29.	4.6	232
32	A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 761-767.	2.0	195
33	The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. <i>Blood</i> , 2015, 125, 3183-3192.	1.4	133
34	Rethinking the paradigm: How comparative studies on fatty acid oxidation inform our understanding of T cell metabolism. <i>Molecular Immunology</i> , 2015, 68, 564-574.	2.2	16
35	Anaplerotic Metabolism of Alloreactive T Cells Provides a Metabolic Approach To Treat Graft-Versus-Host Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 351, 298-307.	2.5	62
36	Improved accuracy of acute graft-versus-host disease staging among multiple centers. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 283-287.	1.7	23

#	ARTICLE	IF	CITATIONS
37	Blood and Marrow Transplant Clinical Trials Network: Progress since the State of the Science Symposium 2007. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 149-153.	2.0	20
38	Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 87-95.	10.7	113
39	Etanercept plus Topical Corticosteroids as Initial Therapy for Grade One Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1426-1434.	2.0	20
40	Engraftment Syndrome after Allogeneic Hematopoietic Cell Transplantation Predicts Poor Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1407-1417.	2.0	80
41	Cellular therapy of the host to prevent GVHD. <i>Blood</i> , 2014, 124, 1703-1704.	1.4	2
42	ST2 as a Marker for Risk of Therapy-Resistant Graft-versus-Host Disease and Death. <i>New England Journal of Medicine</i> , 2013, 369, 529-539.	27.0	339
43	Effector T cells require fatty acid metabolism during murine graft-versus-host disease. <i>Blood</i> , 2013, 122, 3230-3237.	1.4	123
44	Plasma biomarkers of lower gastrointestinal and liver acute GVHD. <i>Blood</i> , 2012, 119, 2960-2963.	1.4	122
45	Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. <i>Blood</i> , 2012, 119, 3854-3860.	1.4	163
46	Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. <i>Blood</i> , 2011, 118, 6702-6708.	1.4	277
47	Elafin Is a Biomarker of Graft-Versus-Host Disease of the Skin. <i>Science Translational Medicine</i> , 2010, 2, 13ra2.	12.4	215
48	Immunotherapy through T-cell receptor gene transfer induces severe graft-versus-host disease. <i>Immunotherapy</i> , 2010, 2, 791-794.	2.0	8
49	Frequency of CD4+CD25hiFOXP3+ Regulatory T Cells Has Diagnostic and Prognostic Value as a Biomarker for Acute Graft-versus-Host-Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 907-914.	2.0	119
50	Graft-versus-host disease. <i>Lancet</i> , The, 2009, 373, 1550-1561.	13.7	2,093
51	A biomarker panel for acute graft-versus-host disease. <i>Blood</i> , 2009, 113, 273-278.	1.4	348
52	Advances in the clinical management of GVHD. <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 677-682.	1.7	31
53	Long-Term follow-up of a Phase I/II Randomized, Placebo-Controlled Trial of Palifermin to Prevent Graft-versus-Host Disease (GVHD) after Related Donor Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1017-1021.	2.0	65
54	Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. <i>Blood</i> , 2008, 111, 2470-2475.	1.4	183

#	ARTICLE	IF	CITATIONS
55	Novel strategies for the treatment and diagnosis of graft-versus-host-disease. Best Practice and Research in Clinical Haematology, 2007, 20, 91-97.	1.7	36
56	Immunobiology of acute graft-versus-host disease. Blood Reviews, 2003, 17, 187-194.	5.7	234
57	Immunogenicity of Ly5 (CD45)-Antigens Hampers Long-Term Engraftment Following Minimal Conditioning in a Murine Bone Marrow Transplantation Model. Stem Cells, 2001, 19, 80-87.	3.2	47
58	The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood, 2000, 95, 2754-2759.	1.4	643
59	Transfusion-Associated Graft-vs-Host Disease. , 0, , 847-857.		1
60	The Pathophysiology of Graft-Versus-Host Disease. , 0, , 208-221.		2